摘要免疫系统在控制和消灭恶性细胞中具有重要作用.近年来,由于免疫检查点抑制剂在血液系统肿瘤治疗中取得显著效果,因此被广泛关注.目前,程序性细胞死亡蛋白(PD)-1/程序性死亡配体-1(PD-L1)单克隆抗体和杀伤细胞免疫球蛋白样受体(KIR)单克隆抗体在该方面的研究较为深入.PD-1/PD-L1单克隆抗体能够逆转抑制效应,激活T细胞杀伤肿瘤细胞的活性,从而在治疗血液系统肿瘤患者中发挥显著临床效果,KIR单克隆抗体则可以增强自然杀伤(NK)细胞的抗肿瘤反应.通过PD-1/PD-L1单克隆抗体联合KIR单克隆抗体动员T细胞和NK细胞这2种不同类型的免疫效应细胞,产生协同的抗肿瘤反应,是一种很有前景的血液系统肿瘤的治疗策略.笔者拟就PD-1/PD-L1单克隆抗体联合KIR单克隆抗体在血液系统肿瘤治疗中的应用进行综述.

abstractsThe immune system plays an important role in the control and elimination of malignant cells.In recent years,immunotherapy for treating tumors has received much attention due to its remarkable effects.There are currently two approaches to lead the field:programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) monoclonal antibody and killer cell immunoglobulin-like receptor (KIR) monoclonal antibody.It has been reported that PD-1/PD-L1 monoclonal antibody can reverse the inhibitory effect of activating T cells to kill tumor cells and thus exert a significant clinical response in patients with hematological tumors.KIR monoclonal antibody enhance the anti-tumor response of natural killer (NK) cells.It is a promising therapeutic strategy to mobilize both T cell and NK cell immune effector cells by PD-1/PD-L1 monoclonal antibody and KIR monoclonal antibody to produce synergistic anti-tumor response.This article intends to review the application of two antibodies in hemotological neoplasms.